Skip to main content

Table 2 Clinical and laboratory characteristics in patients with YOFMF, AOFMF, and LOFMF (univariate analyses)

From: Musculoskeletal manifestations occur predominantly in patients with later-onset familial Mediterranean fever: Data from a multicenter, prospective national cohort study in Japan

Variable YOFMF (n = 182) AOFMF (n = 115) LOFMF (n = 90) p value
YOFMF vs AOFMF vs LOFMF YOFMF vs others Others vs LOFMF
Frequency of febrile attack (/month)a 1.0 (0.3–1.0, n = 157) 1.0 (0.4–1.0, n = 97) 0.5 (0.4–1.0, n = 74) 0.90 0.66 0.66
Duration of fever attack (days)a 2.5 (2–4, n = 165) 3 (2–4.8, n = 101) 2.5 (2–5, n = 71) 0.25 0.25 0.75
Headache 25/161 (16%) 18/91 (20%) 10/65 (15%) 0.65 0.65 0.85
Thoracic pain 82/182 (45%) 38/115 (33%) 22/90 (24%) 0.0025 0.0015 0.0060
Abdominal pain 117/182 (64%) 64/115 (56%) 27/90 (30%) < 0.0001 0.0001 < 0.0001
Pericarditis 3/161 (2%) 3/91 (3%) 4/65 (6%) 0.25 0.21 0.13
Arthritis 58/182 (32%) 55/115 (48%) 56/90 (62%) < 0.0001 < 0.0001 < 0.0001
Myalgia 13/161 (8%) 16/91 (18%) 17/65 (26%) 0.0014 0.0012 0.0051
Erysipelas-like erythema 18/182 (10%) 16/115 (14%) 17/90 (19%) 0.11 0.10 0.076
Good response to colchicine 124/126 (98%) 85/87 (98%) 69/71 (97%) 0.84 0.70 0.64
WBC (× 103/μl)a 10 (7.2–13, n = 126) 9.1 (7.2–12.5, n = 64) 9.1 (7.4–12, n = 48) 0.84 0.65 0.94
CRP (mg/dl)a 7.1 (4.0–12.7, n = 132) 7.1 (2.1–11.1, n = 65) 9.4 (3.4–15, n = 50) 0.12 0.46 0.22
SAA (μg/ml)a 85 (206–1246, n = 43) 423 (55–1100, n = 13) 300 (105–702, n = 9) 0.23 0.10 0.18
ESR (mm/h)a 40 (24–51, n = 39) 41.5 (15.5–56, n = 10) 56 (35–90, n = 15) 0.063 0.075 0.019
IgD (mg/dl)a 4.2 (1.1–10.9, n = 17) 1.5 (1.0–2.3, n = 3) 10 (1.9–18, n = 2) 0.41 0.64 0.46
  1. Median (interquartile range, number) or number (percentage) presented. p values established using Fisher’s exact test or Mann–Whitney U test
  2. YOFMF young-onset FMF, AOFMF adult-onset FMF, LOFMF late-onset FMF, FMF familial Mediterranean fever, WBC white blood cell count, CRP C-reactive protein, SAA serum amyloid A, ESR erythrocyte sedimentation, IgD immunoglobulin D